Genprex announces first patient dosed with Regorsa in Phase 2 lung cancer study
Genprex (GNPX) announced that the first patient has been enrolled and dosed in the Phase 2 expansion portion of the company’s Acclaim-3 ...
Vigil Neuroscience advances Alzheimer's drug to Phase 2 trial
WATERTOWN, Mass. - Vigil Neuroscience , Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company, has announced the progression of its Alzheimer’s disease (AD) candidate, VG-3927, into a Phase 2 ...
pulmonaryfibrosisnews2d
MTX-463 expected to enter Phase 2 testing in IPF in first half of 2025
Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.
FierceBiotech3d
Analysts 'highly encouraged' by TREM2 reduction seen in Vigil's phase 1 Alzheimer's data
Vigil Neuroscience has reported early clinical data on its Alzheimer’s disease candidate, positioning the biotech to advance its small molecule in the footsteps of AbbVie and Alector’s failed rival ...
BioSpace3d
Vigil’s TREM2-Targeted Alzheimer’s Treatment Shows Early Promise, Moves On to Phase II
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially ...
Space.com1d
What is the moon phase today? Lunar phases 2025
What is the moon phase today? Today, Jan. 25, 2025, the moon is 26 days old, in the Waning Crescent phase of its lunar cycle. It is 15% illuminated. Moon phases reveal the passage of time in the ...
Nature4d
Phase transitions and critical phenomena articles from across Nature Portfolio
Long-range interactions have been predicted to enable a phase transition in one-dimensional systems. An experiment now validates this hypothesis in a trapped-ion quantum simulator by observing a ...